CD274 and cancer: Accordingly, the anti-PD-L1/TIGIT combination is the most effective strategy for blocking the growth of cSCCs that contain epithelial, hybrid E/M, and mesenchymal cancer cells through stimulation of both CTLs and NK cells, highlighting that mixed cSCCs should be treated with combined therapies to address both cancer cell components.